REGULATED PRESS RELEASE

from NFL BIOSCIENCES (EPA:ALNFL)

NFL BIOSCIENCES: FINANCIAL CALENDAR FOR 2024

PRESS RELASE

Biosciences

Montpellier, January 9, 2024 - 5:45pm

NFL BIOSCIENCES: FINANCIAL CALENDAR FOR 2024

NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XTO - ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, presents its financial communication calendar for 2024.

image

Date*

2023 annual results

March 29 th 2024

Annual General Meeting (Montpellier)

May 30 th 2024

2024 half-year results

Septem ber 27 th 2024

*Press releases will be published after the close of the stock market

The calendar is provided for information purposes only and may be subject to modification

About NFL Biosciences

image

NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences l ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder.

imageThe shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL). Find out more at www.nflbiosciences.com

Contacts

image

Bruno Lafont -info@nflbiosciences.com - 04 Il 93 76 67                                     Agence Calyptus - nflbio@calyptus.net - 01 53 65 68 68

1

See all NFL BIOSCIENCES news